Abstract 2042P
Background
Breast cancer is the most diagnosed cancer affecting Australian women. While the incidence rate of breast cancer is lower in indigenous women than non-indigenous women the mortality rate is higher, with indigenous women 1.2 times more likely to die from the disease. The are many factors that contribute to this and if we want outcomes to improve for indigenous women with breast cancer, we must identify where practice and policy can change and improve. These findings may inform approaches for indigenous women in other high-income countries who experience similarly poor breast cancer outcomes.
Methods
This research employed the Context-Mechanism-Outcome (CMO) framework to reveal potential mechanisms and contextual factors that influence breast cancer outcomes for indigenous women. The framework explains generative causation, which helps to highlight the relationship between a context, mechanism, and outcome of a program or policy. The mechanisms and contextual factors were stratified into multiple levels; micro (interpersonal), meso (systemic), and macro (policy) levels. “If-Then-Because” statements were used to represent (broadly) the elements of CMO.
Results
The CMO framework allowed us to interpret evidence regarding indigenous women and breast cancer and provided nine practical ways to improve health outcomes and survival rates: 1. Improved health literacy regarding the importance of screening and early detection, delivered in a culturally safe way 2. Increased cultural safety and access to screening services 3. Presence of indigenous health service providers 4. Ensuring health service provider is local and/or familiar with indigenous culture and community 5. Culturally safe screening, diagnosis, treatment and follow-up settings 6. Local indigenous screening champions in the community 7. Protocols for abnormal results are tailored to local setting and community 8. Culturally safe support available for people who receive diagnoses 9. Policy is re-written in consultation with indigenous people and provides solutions to improve health outcomes.
Conclusions
Using the CMO framework, this study has provided nine practical measures to assist in improving the health outcomes for Australian indigenous women with breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. Christie.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06